Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Melanoma

Melanoma, also known as malignant melanoma, occurs when abnormal skin cells multiply rapidly in an uncontrolled way.

Research

Brain Tumour

Brain tumours are the second most common cancer in children (after leukaemia).

Research

Language Development

Language is one of the most remarkable developmental accomplishments of early childhood. Language connects us with others and is an essential tool for literacy, education, employment and lifelong learning.

The decades old program helping families and kids to thrive

It’s a brave move to upend your entire family to seek a fresh start – or safety – in a new country: even braver when the country you’re moving to has a completely different language, structure and cultural outlook.

Early detection helps delay onset of diabetes

A world-first study led by Dr Aveni Haynes at The Kids’ Rio Tinto Children’s Diabetes Centre, is helping to detect early changes in blood sugar levels.

Community and action at the heart of Journey Together project

A unique initiative is combining research, action and advocacy to deliver evidence- based improvements to the health and wellbeing of Aboriginal families in Perth and Western Australia’s north west.

Unravelling medical mysteries for kids with undiagnosed diseases

Three hundred and fifty million people live with an undiagnosed disease worldwide and three quarters of them are children.

Researchers call for rethink on infant screentime

A The Kids Research Institute Australia study has found the average six-month-old Australian baby has more than one hour of screen time each day.

Putting malaria on the MAP

The Kids Research Institute Australia is at the forefront of a global effort to track and prevent malaria – one of the world’s leading causes of disease and child deaths, particularly in developing countries.

Research

Rethinking a hybrid malaria chemoprevention delivery strategy for children in sub-perennial settings: a modelling study integrating age- and seasonally-targeted delivery

The World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulfadoxine-pyrimethamine (SP) to children at high risk of severe Plasmodium falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as 'sub-perennial'.